Combination Therapy with Mitoxantrone and Etoposide in Adult Acute Myelogenous Leukemia

  • W. U. Knauf
  • A. D. Ho
  • M. Körbling
  • W. Hunstein
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 33)


Complete remission (CR) rate in adult acute myelogenous leukemia (AML) was improved by the use of aggressive chemotherapy. Today, more than 70% of patients can achieve a CR [1, 2]. But the relapse rate remains high as well as the rate of failure to therapy in myelodysplasia transformed into overt AML. Moreover, so far the value of aggressive chemotherapy is not clarified in the case of a relapse after intensive treatment like autologous blood stem cell transplantation (ABSCT). Mitoxantrone and etoposide have both been shown to be effective as single agents in the treatment of AML [3-6] and the ability to induce a CR in refractory AML was proven for a combination of the two [7]. We therefore studied the effectiveness of a combination therapy of mitoxantrone and etoposide as first-line therapy in AML, myelodysplasia syndromes (MDSs) transformed into AML, and salvage therapy in AML relapsed after ABSCT.


Acute Myeloid Leukemia Complete Remission Acute Leukemia Acute Myelogenous Leukemia Complete Remission Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Büchner T for the AML Cooperative Group (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3: 1583–1589Google Scholar
  2. 2.
    Gale RP (1979) Advances in the treatment of acute myelogenous leukemia. N Engl J Med 300: 1189–1197PubMedCrossRefGoogle Scholar
  3. 3.
    Paciucci PA, Olmuma T, Cuttner J, Silver RT, Holland JF (1983) Mitoxantrone in patients with acute leukemia in relapse. Cancer Res 43: 3919–3922PubMedGoogle Scholar
  4. 4.
    Prentice HG, Robbins G, Ma DDF, Ho AD (1984) Mitoxantrone in relapsed and refractory acute leukemia. Semin Oncol 11 [Suppl 1]: 32–35PubMedGoogle Scholar
  5. 5.
    Bennett JM, Lymann GG, Cassileth PA (1984) A phase II trial of VP-16-213 in adults with refractory acute myeloid leukemia. Am J Clin Oncol 7: 471–473PubMedCrossRefGoogle Scholar
  6. 6.
    O’Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE (1985) Etoposide (VP- 16-213) -current status of an active anticancer drug. N Engl J Med 312: 692–700PubMedCrossRefGoogle Scholar
  7. 7.
    Ho AD, Lipp T, Ehninger G, Meyer P, Freund M, Hunstein W (1986) Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia. Cancer Treat Rep 70: 1025–1027PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • W. U. Knauf
    • 1
  • A. D. Ho
    • 1
  • M. Körbling
    • 1
  • W. Hunstein
    • 1
  1. 1.Dept. of Internal Medicine-PoliklinikUniversityHeidelbergGermany

Personalised recommendations